CA2529400A1 — Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
Assigned to Merck Sharp and Dohme LLC · Expires 2005-01-13 · 21y expired
What this patent protects
The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[1,2,4]triazolo[4,3-alpha]pyrazin-7(8H)-yl]-1-(2,4,5- trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase- IV and is useful for the prevention and/or treatment of non-insulin dependen…
USPTO Abstract
The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[1,2,4]triazolo[4,3-alpha]pyrazin-7(8H)-yl]-1-(2,4,5- trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase- IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing thi s novel form and methods of use for the treatment of diabetes, obesity, and hi gh blood pressure.
Drugs covered by this patent
- Steglatro (ERTUGLIFLOZIN) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.